Nivolumab-induced severe ulcerative colitis
10.3760/cma.j.cn114015-20210609-00656
- VernacularTitle:纳武利尤单抗致重度溃疡性结肠炎
- Author:
Yu LIANG
1
;
Zhen MENG
1
;
Donghua LIU
1
;
Huaiqin CANG
1
;
Hongyan JI
1
;
Xue YANG
1
;
Xianghua QUAN
1
Author Information
1. 青岛大学附属医院药学部，青岛 266003
- Publication Type:Journal Article
- Keywords:
Nivolumab;
Colitis ulcerative;
Diarrhea
- From:
Adverse Drug Reactions Journal
2022;24(3):159-161
- CountryChina
- Language:Chinese
-
Abstract:
A 64-year-old male patient with gastric adenocarcinoma received chemotherapy with oxaliplatin (250 mg intravenous infusion on day 1) and tegafur gimeracil oteracil potassium (60 mg orally twice daily on day 1 to day 14, 21 days as a cycle). One month later, he was given nivolumab immunotherapy (240 mg intravenous infusion on day 1, 14 days as a cycle). On the 2nd day of the 4th cycle of nivolumab treatment (the 44th day after the first dose), the patient developed diarrhea with watery stools, 3 to 4 times a day, accompanied by mild abdominal pain; 3 days later, the diarrhea worsened, showing dark red bloody stools, covered with pus moss, up to 10 times a day, accompanied by obvious abdominal pain. According to colonoscopy and histological examination results, ulcerative colitis (initial onset, total colon, active stage, and severe) was diagnosed, which was considered as a grade 3 immune-related colitis induced by nivolumab. After suspension of chemotherapy and immunotherapy, and administration of glucocorticoids and octreotide, the patient′s abdominal pain and diarrhea were gradually improved. On the 45th day of nivolumab withdrawal, the patient received chemotherapy with oxaliplatin and tegafur gimeracil oteracil potassium again, and colitis did not recur.
